To verify the efficacy of a cisplatin-based chemotherapeutic approach with breast cancer, we treated the triple-negative breast cancer cell line (MDA-MB-231), estrogen-receptor lacking breast cancer line (MCF7) and normal breast epithelial cell line (MCF10A) with 20 μM cisplatin for four hours before the phasor-FLIM acquisition (Figure 2). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.